Next 10 |
home / stock / alxo / alxo articles
Mesoblast Limited (NASDAQ: MESO) has witnessed a phenomenal run in the year so far. Shares of MESO have risen a whopping 208.2% year to date a...
Denali Therapeutics Inc. (NASDAQ: DNLI) is having a good run in 2024. Shares of this biopharmaceutical company have risen 11.9% in the past three m...
Novo Nordisk (NYSE: NVO) lost 2.2% on Jun 26 after the company announced the failure of a late-stage study evaluating ocedurenone to trea...
Gilead Sciences, Inc. (NASDAQ: GILD) announced upbeat top-line results from an interim analysis of its late-stage study PURPOSE 1. PURPOSE 1 is a p...
Moderna, Inc. (NASDAQ: MRNA) announced that it has submitted an application to the FDA seeking approval of its Spikevax 2024-2025 formula, tar...
Halozyme Therapeutics (NASDAQ: HALO) announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which ...
Intellia Therapeutics' (NASDAQ: NTLA) shares gained 10% on Jun 3 after the company reported encouraging long-term data from the phase I portion...
AbbVie (NYSE: ABBV) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has a...
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an im...
News, Short Squeeze, Breakout and More Instantly...
ALX Oncology Holdings Inc. Company Name:
ALXO Stock Symbol:
NASDAQ Market:
ALX Oncology Holdings Inc. Website:
Evorpacept in combination with PADCEV ® , an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well tolerated Company to host conference call and webcast with Samuel A. Funt, M.D., of Memorial Sloan Kettering Cancer Center on ...
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that management wi...
2024-05-10 08:30:07 ET H.C. Wainwright analyst issues BUY recommendation for ALXO on May 10, 2024 06:40AM ET. The previous analyst recommendation was Buy. ALXO was trading at $16.95 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...